These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37141665)

  • 1. Chemotherapy induced phlebitis experienced by women with breast cancer following administration of epirubicin using a volumetric infusion pump: an observational study.
    Williams N; Williams EM; Roberts R
    Eur J Oncol Nurs; 2023 Jun; 64():102322. PubMed ID: 37141665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis.
    Roberts R; Hanna L; Borley A; Dolan G; Williams EM
    Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13114. PubMed ID: 31148328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Risk Factors for Anthracycline Chemotherapy-induced Phlebitis in Women with Breast Cancer: An Observational Study.
    Roberts R; Borley A; Hanna L; Dolan G; Ganesh S; Williams EM
    Clin Oncol (R Coll Radiol); 2021 Apr; 33(4):230-240. PubMed ID: 33308947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin.
    Nagata K; Egashira N; Yamada T; Watanabe H; Yamauchi Y; Oishi R
    Support Care Cancer; 2012 May; 20(5):951-5. PubMed ID: 21519948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation].
    Suga Y; Kumazaki M; Nishigami J; Takeda K; Kawagishi A; Ishizaki J; Inokuchi M; Miyamoto K; Arai K
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):93-6. PubMed ID: 19151570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer].
    Ono C; Yamagami M; Kamatani R; Yamamoto M; Mukouyama T; Sugimoto M; Suzuki T; Kamo N; Seki N; Eguchi K; Ikeda T
    Gan To Kagaku Ryoho; 2012 May; 39(5):777-81. PubMed ID: 22584330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
    Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Feasibility and toxicity of EC-T dose-dense adjuvant chemotherapy: A real world study in Chinese early-stage breast cancer patients with high recurrence risk].
    Wang JN; Mu YX; Li Q; Fan Y; Wang JY; Ma F; Luo Y; Yuan P; Chen SS; Li Q; Cai RG; Zhang P; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):368-372. PubMed ID: 31137171
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
    Basser RL; Abraham R; To LB; Fox RM; Green MD
    Ann Oncol; 1999 Jan; 10(1):53-8. PubMed ID: 10076722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles.
    Baptista RJ; Driscoll DF; Gallagher JA; O'Keefe E; Dumas GJ; Hammer SM; Pacella PP
    Clin Pharm; 1987 Apr; 6(4):314-8. PubMed ID: 3665384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
    Cho EK; Lee WK; Lim DY; Bang SM; Park DK; Park YH; Kwon OS; Choi DJ; Shin DB; Lee JH; Lee TH
    J Korean Med Sci; 2002 Jun; 17(3):348-52. PubMed ID: 12068138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of phlebitis associated with the use of peripheral IV catheter and following catheter removal.
    Urbanetto Jde S; Peixoto CG; May TA
    Rev Lat Am Enfermagem; 2016 Aug; 24():e2746. PubMed ID: 27508916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of chemotherapy infusion and phlebitis among cancer patients: A prospective observational single-center study.
    Sudhakar S; Jacob A; Hegde NN; Chaudhary RK; Mateti UV; Shetty V
    J Oncol Pharm Pract; 2023 Dec; 29(8):1944-1950. PubMed ID: 36872649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
    Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
    Gurney H; Harnett P; Stuart-Harris R; Kefford R
    Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
    Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
    Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity.
    Sun F; Qi X; Geng C; Li X
    Am J Med Sci; 2015 May; 349(5):406-12. PubMed ID: 25723884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.